David Amsellem
Stock Analyst at Piper Sandler
(4.86)
# 75
Out of 5,112 analysts
164
Total ratings
68.46%
Success rate
25.98%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $147 → $219 | $164.92 | +32.80% | 15 | Dec 10, 2025 | |
| ESPR Esperion Therapeutics | Initiates: Overweight | $9 | $3.65 | +146.58% | 1 | Nov 25, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $118 → $157 | $172.10 | -8.77% | 3 | Nov 21, 2025 | |
| AMGN Amgen | Maintains: Overweight | $342 → $381 | $326.01 | +16.87% | 6 | Nov 14, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Overweight | $5 → $8 | $5.63 | +42.10% | 2 | Nov 7, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Neutral | $6 → $8 | $6.99 | +14.45% | 6 | Nov 7, 2025 | |
| ABBV AbbVie | Reiterates: Overweight | $284 → $289 | $224.31 | +28.84% | 2 | Nov 5, 2025 | |
| INDV Indivior | Reiterates: Overweight | $27 → $41 | $35.95 | +14.05% | 6 | Oct 31, 2025 | |
| AMRX Amneal Pharmaceuticals | Reiterates: Overweight | $11 → $13 | $12.33 | +5.43% | 5 | Oct 31, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $175 → $179 | $141.70 | +26.32% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $45 | $28.04 | +60.49% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $48.75 | +33.33% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $26.07 | -4.10% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $82.28 | +47.06% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $6.99 | +157.51% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $48.90 | -24.34% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $53.55 | +21.38% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $11.70 | -14.53% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $30.06 | -0.20% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $21.41 | -39.28% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $82.35 | -17.43% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.82 | -56.01% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $26.55 | +58.19% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.37 | +523.15% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $148.00 | -23.65% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $38.78 | +8.30% | 3 | Oct 16, 2023 |
Jazz Pharmaceuticals
Dec 10, 2025
Reiterates: Overweight
Price Target: $147 → $219
Current: $164.92
Upside: +32.80%
Esperion Therapeutics
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $3.65
Upside: +146.58%
Biogen
Nov 21, 2025
Reiterates: Neutral
Price Target: $118 → $157
Current: $172.10
Upside: -8.77%
Amgen
Nov 14, 2025
Maintains: Overweight
Price Target: $342 → $381
Current: $326.01
Upside: +16.87%
Aquestive Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $5.63
Upside: +42.10%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $6.99
Upside: +14.45%
AbbVie
Nov 5, 2025
Reiterates: Overweight
Price Target: $284 → $289
Current: $224.31
Upside: +28.84%
Indivior
Oct 31, 2025
Reiterates: Overweight
Price Target: $27 → $41
Current: $35.95
Upside: +14.05%
Amneal Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $12.33
Upside: +5.43%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $141.70
Upside: +26.32%
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $28.04
Upside: +60.49%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $48.75
Upside: +33.33%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $26.07
Upside: -4.10%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $82.28
Upside: +47.06%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $6.99
Upside: +157.51%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $48.90
Upside: -24.34%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $53.55
Upside: +21.38%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $11.70
Upside: -14.53%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $30.06
Upside: -0.20%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $21.41
Upside: -39.28%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $82.35
Upside: -17.43%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.82
Upside: -56.01%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $26.55
Upside: +58.19%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.37
Upside: +523.15%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $148.00
Upside: -23.65%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $38.78
Upside: +8.30%